DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,208,000 | +137.7% | 34,200 | +149.6% | 0.29% | +143.0% |
| Q1 2023 | $3,452,948 | +200.4% | 13,700 | +216.3% | 0.12% | +128.3% |
| Q4 2022 | $1,149,534 | +217.6% | 4,331 | +209.4% | 0.05% | +231.2% |
| Q3 2022 | $362,000 | -86.3% | 1,400 | -86.6% | 0.02% | -82.8% |
| Q2 2022 | $2,649,000 | -34.4% | 10,450 | -24.1% | 0.09% | -21.8% |
| Q1 2022 | $4,039,000 | -58.9% | 13,769 | -53.9% | 0.12% | -18.5% |
| Q4 2021 | $9,817,000 | +61.5% | 29,841 | +31.8% | 0.15% | +32.7% |
| Q2 2021 | $6,077,000 | +172.8% | 22,642 | +128.7% | 0.11% | +134.0% |
| Q1 2021 | $2,228,000 | -84.3% | 9,900 | -84.5% | 0.05% | -87.4% |
| Q4 2020 | $14,197,000 | +21.7% | 63,908 | -3.1% | 0.37% | +84.2% |
| Q2 2020 | $11,664,000 | +66.2% | 65,964 | +30.1% | 0.20% | -48.7% |
| Q1 2020 | $7,019,000 | +849.8% | 50,709 | +953.8% | 0.39% | +3481.8% |
| Q4 2019 | $739,000 | -58.8% | 4,812 | -64.6% | 0.01% | -75.0% |
| Q1 2019 | $1,795,000 | +58.0% | 13,600 | +30.1% | 0.04% | +109.5% |
| Q3 2018 | $1,136,000 | -22.0% | 10,457 | -29.1% | 0.02% | -22.2% |
| Q2 2018 | $1,456,000 | +168.6% | 14,757 | +166.3% | 0.03% | +200.0% |
| Q1 2018 | $542,000 | -98.0% | 5,542 | -98.1% | 0.01% | -97.5% |
| Q4 2017 | $26,816,000 | +155.5% | 288,888 | +136.1% | 0.36% | +150.0% |
| Q3 2017 | $10,494,000 | -16.2% | 122,334 | -17.6% | 0.14% | -2.7% |
| Q2 2017 | $12,526,000 | +90.2% | 148,429 | +92.8% | 0.15% | +85.0% |
| Q1 2017 | $6,584,000 | +230.2% | 76,978 | +200.4% | 0.08% | +300.0% |
| Q4 2016 | $1,994,000 | +248.0% | 25,624 | +250.9% | 0.02% | +185.7% |
| Q3 2016 | $573,000 | -91.5% | 7,303 | -89.1% | 0.01% | -90.5% |
| Q2 2016 | $6,774,000 | +45.7% | 67,068 | +36.8% | 0.07% | -2.6% |
| Q1 2016 | $4,650,000 | +40.1% | 49,014 | +37.1% | 0.08% | -13.6% |
| Q4 2015 | $3,319,000 | +61.8% | 35,746 | +48.5% | 0.09% | +87.2% |
| Q3 2015 | $2,051,000 | -22.4% | 24,074 | -22.7% | 0.05% | -37.3% |
| Q1 2015 | $2,644,000 | +462.6% | 31,145 | +404.0% | 0.08% | +240.9% |
| Q3 2014 | $470,000 | +35.8% | 6,180 | +37.8% | 0.02% | +29.4% |
| Q4 2013 | $346,000 | -2.3% | 4,486 | -12.1% | 0.02% | +21.4% |
| Q3 2013 | $354,000 | -61.5% | 5,101 | -64.9% | 0.01% | -72.5% |
| Q2 2013 | $920,000 | – | 14,527 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |